Edited by James Chalmers and Stefano Aliberti
Volume 13 Supplement 1
Bronchiectasis: still an orphan disease?
Proceedings
Publication of this supplement was funded by Novamedia and Italian Respiratory Society (IRS). The articles have undergone the journal's standard peer review process for supplements. SA is an associate editor of Multidisciplinary Respiratory Medicine, also a speaker or on advisory boards on bronchiectasis, non-tuberculous mycobacteria and low respiratory tract infection for the following: Bayer, Insmed, Cheiesi, Menarini, Mundipharma, GlaxoSmithKline, AstraZeneca, Grifols, Guidotti, Malesci, Zambon, Quinsair, Actavis, Novartis, BI, Raptor, Horizon Pharma. JC has recevied research grants from Aradigm Corporation, Bayer Healthcare, Grifols, AstraZeneca, GlaxoSmithKline and Boehringer-Ingelheim. JC also received consulting fees from Aradigm Corporation, Bayer Healthcare, Grifols, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Pfizer and Napp.
Milan, Italy06-08 July 2017
-
Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):28
-
Bronchiectasis in PCD looks different to CF on CT scan
The contemporary diagnosis of bronchiectasis requires CT scanning to describe specific structural lung changes. Scoring systems have been designed and validated in some specific causes of bronchiectasis to all...
Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):24 -
Understanding the impact of antibiotic therapies on the respiratory tract resistome: a novel pooled-template metagenomic sequencing strategy
Determining the effects of antimicrobial therapies on airway microbiology at a population-level is essential. Such analysis allows, for example, surveillance of antibiotic-induced changes in pathogen prevalenc...
Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):30 -
The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol
A substantial increase in pulmonary and extra-pulmonary diseases due to non-tuberculous mycobacteria (NTM) has been documented worldwide, especially among subjects suffering from chronic respiratory diseases a...
Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):33 -
When and how ruling out cystic fibrosis in adult patients with bronchiectasis
Bronchiectasis is the final result of different processes and most of the guidelines advocate for a careful evaluation of those etiologies which might be treated or might change patients’ management, including...
Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):29 -
Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis
Bronchiectasis represents the final pathway of several infectious, genetic, immunologic or allergic disorders. Accurate and prompt identification of the underlying cause is a key recommendation of several inte...
Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):26